J.D. Pharma Consultants Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 05-07-2024
- Paid Up Capital ₹ 0.10 M
as on 05-07-2024
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 2826.58%
(FY 2023)
- Profit 2142.17%
(FY 2023)
- Ebitda 8766.89%
(FY 2023)
- Net Worth 104.42%
(FY 2023)
- Total Assets 1685.82%
(FY 2023)
About J.D. Pharma Consultants
The Company is engaged in the Engineering Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jyoti Kara and Vaibhav Kara serve as directors at the Company.
- CIN/LLPIN
U74999MP2016PTC041184
- Company No.
041184
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jul 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does J.D. Pharma Consultants Private Limited offer?
J.D. Pharma Consultants Private Limited offers a wide range of products and services, including Turnkey Consultants & Solutions, Industrial project consultants, Pharmaceutical Machinery & Equipment, Capsule Filling Machines, Architectural & Civil Engineering, Architectural Services, Plant Design & Installation Services, Industrial Equipment Installation, Graphic Design & Animation Services, Designing Services.
Who are the key members and board of directors at J.D. Pharma Consultants?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jyoti Kara  | Whole-Time Director | 16-Oct-2017 | Current |
| Vaibhav Kara | Whole-Time Director | 20-Jul-2016 | Current |
Financial Performance of J.D. Pharma Consultants.
J.D. Pharma Consultants Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 2826.58% increase. The company also saw a substantial improvement in profitability, with a 2142.17% increase in profit. The company's net worth Soared by an impressive increase of 104.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of J.D. Pharma Consultants?
In 2023, J.D. Pharma Consultants had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Integrated Farming Network India Private LimitedActive 9 years 4 monthsVaibhav Kara is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at J.D. Pharma Consultants?
Unlock and access historical data on people associated with J.D. Pharma Consultants, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of J.D. Pharma Consultants, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped J.D. Pharma Consultants's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
